Aridis Pharmaceuticals (ARDS)
(Delayed Data from OTC)
$0.06 USD
-0.01 (-12.50%)
Updated Jun 12, 2024 03:32 PM ET
3-Hold of 5 3
C Value A Growth C Momentum B VGM
Brokerage Reports
0 items in cart
Aridis Pharmaceuticals [ARDS]
Reports for Purchase
Showing records 41 - 51 ( 51 total )
Company: Aridis Pharmaceuticals
Industry: Medical - Biomedical and Genetics
AR-501 Safe in Healthy Volunteers - Seeking Efficacy in CF Patients Next
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Aridis Pharmaceuticals
Industry: Medical - Biomedical and Genetics
COVID-19 Creates a Delay but Also an Opportunity; Reit Buy With New $11 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Aridis Pharmaceuticals
Industry: Medical - Biomedical and Genetics
Company: Aridis Pharmaceuticals
Industry: Medical - Biomedical and Genetics
1Q20: Maintains Guidance of Slight Phase 3 COVID-19 Delay, Cash Thru 2020
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Aridis Pharmaceuticals
Industry: Medical - Biomedical and Genetics
Key Takeaways From KOL Call on ARDS and COVID-19
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Aridis Pharmaceuticals
Industry: Medical - Biomedical and Genetics
Company: Aridis Pharmaceuticals
Industry: Medical - Biomedical and Genetics
Slight Phase 3 Trial Delay from COVID-19, Intact Otherwise - Reports 4Q19
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Aridis Pharmaceuticals
Industry: Medical - Biomedical and Genetics
32nd Annual Conference: Jonathan Aschoff''s Biotechnology Track Overview
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Aridis Pharmaceuticals
Industry: Medical - Biomedical and Genetics
Company: Aridis Pharmaceuticals
Industry: Medical - Biomedical and Genetics
Catalyst Rich 2020, Phase 3 Results in 1H21 - New Approach to Resistance
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Aridis Pharmaceuticals
Industry: Medical - Biomedical and Genetics
When Stepping to the Front of the Line Would Be a Good Thing; Initiating at Buy With an $7 Price Target
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V